LexisNexis® Risk Solutions today announced it has completed an agreement with its sister company Elsevier to transfer MEDai, its clinical-analytics-focused business unit, to the LexisNexis health care business. LexisNexis Risk Solutions and Elsevier are both part of Reed Elsevier Group plc. The combined organization will allow LexisNexis to offer a more comprehensive set of cost-containment solutions to curtail wasteful spending, help coordinate better care, improve population health management, enhance clinical outcomes and reduce exposure to fraud, waste and abuse (FWA).
This announcement comes as health care organizations strive to accomplish three critical goals driven by the Affordable Care Act (ACA): improve access to health care, improve outcomes and reduce overall costs. In order to achieve progress against these priorities, many payer and provider organizations are deploying technology at an enterprise level to address and align the needs of various operational workflows.
"This transfer of businesses underscores our commitment to provide and continuously improve our health care solutions, especially in the areas of fraud, identity and clinical analytics," said Lee Rivas, CEO Public Sector and Health Care. "Our member, provider and claims management solutions, alongside MEDai's expertise in analyzing the clinical implications of providers delivering care to members provides customers a distinct advantage. Our combined group offers customers the right solutions to make critical, confident decisions that align with the ACA and improve the health of their customers."
This transfer follows LexisNexis' fall 2012 acquisition of EDIWatch, a provider of fraud, waste and abuse (FWA) technology solutions exclusively for the health care payer industry. Through that acquisition, LexisNexis added products to address FWA detection, recovery, and prevention while leveraging automated business fraud rules and analytics and adding user-friendly case management workflow tools and investigatory services.
About LexisNexis Risk Solutions
LexisNexis Risk Solutions (lexisnexis.com/risk/) is a leader in providing essential information that helps customers across industries and government predict, assess and manage risk. Combining cutting-edge technology, unique data and advanced analytics, Risk Solutions provides products and services that address evolving client needs in the risk sector while upholding the highest standards of security and privacy. LexisNexis Risk Solutions is part of Reed Elsevier, a leading global provider of professional information solutions across a number of sectors.
Our health care solutions assist payers, providers and integrators with ensuring appropriate access to health care data and programs, enhancing disease management contact ratios, improving operational processes, and proactively combating fraud, waste and abuse across the continuum.
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include ScienceDirect, Scopus, Reaxys, ClinicalKey and Mosby's Suite, which enhance the productivity of science and health professionals, and the SciVal suite, which help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group plc, a world leading provider of professional information solutions.
About Reed Elsevier Group plc
Reed Elsevier Group plc is a world leading provider of professional information solutions. The group employs approximately 30,000 people of whom half are in North America. Reed Elsevier Group PLC is owned equally by two parent companies, Reed Elsevier PLC and Reed Elsevier NV; the combined market capitalisation of the two parent companies is approximately £17bn/€19bn. Their shares are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RUK and ENL.